Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform
of 5.23 µM. Western blot analyses in SEM cells revealed that the lead compound 7a bound to its intracellular target, resulting in an approximately 59% reduction in total HDAC-2 protein levels. Flow cytometry revealed that a significant reduction in HDAC-2 led to cancer cells being arrested at the key G2/M phase of the cell cycle, with 46.22% of cells detained there compared to merely 7.21% in untreated controls. Subsequent analysis using Annexin V/PI labeling demonstrated that this cell cycle arrest results in a significant elevation of programmed cell death, increasing total apoptosis to 31.12%, while maintaining non-specific necrosis at a minimal 4.29%. Taken together, these findings indicate that the 4-iodo-3-nitrophenyl compounds are effective tools for the targeted treatment of leukemia, displaying preferential HDAC-2 inhibitory activity among the evaluated class I isoforms.
Authors
- Abdullah Yahya Abdullah Alzahrani (ORCID: https://orcid.org/0000-0001-5231-8932)
- Bahaa G. M. Youssif (ORCID: https://orcid.org/0000-0002-6834-6548)
- Bandar A. Alyami (ORCID: https://orcid.org/0000-0002-6374-917X)
- Fatma Elzahraa Ali (ORCID: https://orcid.org/0009-0009-4194-8184)
- Stefan Bräse (ORCID: https://orcid.org/0000-0003-4845-3191)
- Anber F. Mohammed
Institutions
- Karlsruhe Institute of Technology (DE)
- Najran University (SA)
- King Khalid University (SA)
- Assiut University (EG)
Publication Details
- Journal
- RSC Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1039/d6ra08049a
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Karlsruhe Institute of Technology